��������

Paul Hargreaves is a highly experienced professional in the biopharmaceutical and MedTech industries, currently serving as Chief Development Officer at Spago Nanomedical AB since October 2021. Hargreaves is also an external advisor at Copenhagen Business School for the Executive MBA program and a board member for the MBA Alumni Association. Previous roles include Chief Development Officer at Roxiant and ResoTher Pharma ApS, and Vice President at LEO Pharma, where leadership spanned global clinical operations and project management. Hargreaves has consulted for biopharmaceutical companies and financial institutions, focusing on clinical development strategies and operational effectiveness. Academic credentials include an Executive MBA from Copenhagen Business School and advanced degrees in Clinical Pharmacology and Physiology/Pharmacology from the University of Aberdeen and The University of Manchester, respectively.